ID   KGP1_RABIT              Reviewed;         671 AA.
AC   O77676;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   07-APR-2021, entry version 137.
DE   RecName: Full=cGMP-dependent protein kinase 1;
DE            Short=cGK 1;
DE            Short=cGK1;
DE            EC=2.7.11.12;
GN   Name=PRKG1;
OS   Oryctolagus cuniculus (Rabbit).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Lagomorpha; Leporidae; Oryctolagus.
OX   NCBI_TaxID=9986;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=New Zealand white; TISSUE=Heart;
RX   PubMed=10565812;
RA   Kumar R., Joyner R.W., Komalavilas P., Lincoln T.M.;
RT   "Analysis of expression of cGMP-dependent protein kinase in rabbit heart
RT   cells.";
RL   J. Pharmacol. Exp. Ther. 291:967-975(1999).
RN   [2]
RP   FUNCTION IN PHOSPHORYLATION OF RGS4.
RX   PubMed=16885398; DOI=10.1152/ajpcell.00103.2006;
RA   Huang J., Zhou H., Mahavadi S., Sriwai W., Murthy K.S.;
RT   "Inhibition of Galphaq-dependent PLC-beta1 activity by PKG and PKA is
RT   mediated by phosphorylation of RGS4 and GRK2.";
RL   Am. J. Physiol. 292:C200-C208(2007).
CC   -!- FUNCTION: Serine/threonine protein kinase that acts as key mediator of
CC       the nitric oxide (NO)/cGMP signaling pathway. GMP binding activates
CC       PRKG1, which phosphorylates serines and threonines on many cellular
CC       proteins. Numerous protein targets for PRKG1 phosphorylation are
CC       implicated in modulating cellular calcium, but the contribution of each
CC       of these targets may vary substantially among cell types. Proteins that
CC       are phosphorylated by PRKG1 regulate platelet activation and adhesion,
CC       smooth muscle contraction, cardiac function, gene expression, feedback
CC       of the NO-signaling pathway, and other processes involved in several
CC       aspects of the CNS like axon guidance, hippocampal and cerebellar
CC       learning, circadian rhythm and nociception. Smooth muscle relaxation is
CC       mediated through lowering of intracellular free calcium, by
CC       desensitization of contractile proteins to calcium, and by decrease in
CC       the contractile state of smooth muscle or in platelet activation.
CC       Regulates intracellular calcium levels via several pathways:
CC       phosphorylates IRAG1 and inhibits IP3-induced Ca(2+) release from
CC       intracellular stores, phosphorylation of KCNMA1 (BKCa) channels
CC       decreases intracellular Ca(2+) levels, which leads to increased opening
CC       of this channel. PRKG1 phosphorylates the canonical transient receptor
CC       potential channel (TRPC) family which inactivates the associated inward
CC       calcium current. Another mode of action of NO/cGMP/PKGI signaling
CC       involves PKGI-mediated inactivation of the Ras homolog gene family
CC       member A (RhoA). Phosphorylation of RHOA by PRKG1 blocks the action of
CC       this protein in myriad processes: regulation of RHOA translocation;
CC       decreasing contraction; controlling vesicle trafficking, reduction of
CC       myosin light chain phosphorylation resulting in vasorelaxation.
CC       Activation of PRKG1 by NO signaling alters also gene expression in a
CC       number of tissues. In smooth muscle cells, increased cGMP and PRKG1
CC       activity influence expression of smooth muscle-specific contractile
CC       proteins, levels of proteins in the NO/cGMP signaling pathway, down-
CC       regulation of the matrix proteins osteopontin and thrombospondin-1 to
CC       limit smooth muscle cell migration and phenotype. Regulates
CC       vasodilator-stimulated phosphoprotein (VASP) functions in platelets and
CC       smooth muscle (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:16885398}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.12;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.12;
CC   -!- ACTIVITY REGULATION: In the absence of cGMP, PRKG1 activity is
CC       suppressed by autoinhibitory contacts. {ECO:0000250}.
CC   -!- SUBUNIT: Isoform alpha: parallel homodimer or heterodimer and also
CC       heterotetramer. Interacts directly with PPP1R12A. Non-covalent dimer of
CC       dimer of PRKG1-PRKG1 and PPP1R12A-PPP1R12A. This interaction targets
CC       PRKG1 to stress fibers to mediate smooth muscle cell relaxation and
CC       vasodilation in responses to rises in cGMP (By similarity). Isoform
CC       beta: antiparallel homodimer. Part of cGMP kinase signaling complex at
CC       least composed of ACTA2/alpha-actin, CNN1/calponin H1,
CC       PLN/phospholamban, PRKG1 and ITPR1. Interacts with IRAG1 (By
CC       similarity). Forms a stable complex with ITPR1, IRAG1, and isoform beta
CC       of PRKG1 (By similarity). Interacts with TRPC7 (via ankyrin repeat
CC       domain) (By similarity). Isoform alpha interacts with RGS2 (By
CC       similarity). Interacts with GTF2I (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Note=Colocalized with
CC       TRPC7 in the plasma membrane. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Alpha; Synonyms=CGK1-alpha;
CC         IsoId=O77676-1; Sequence=Displayed;
CC       Name=Beta; Synonyms=CGK1-beta;
CC         IsoId=O77676-2; Sequence=Not described;
CC   -!- DOMAIN: Composed of an N-terminal leucine-zipper domain followed by an
CC       autoinhibitory domain, which mediate homodimer formation and inhibit
CC       kinase activity, respectively. Next, two cGMP-binding domains are
CC       followed by the catalytic domain at the C-terminus. Binding of cGMP to
CC       cGMP-binding domains results in a conformational change that activates
CC       kinase activity by removing the autoinhibitory domain from the
CC       catalytic cleft leaving the catalytic domain free to phosphorylate
CC       downstream substrates. Isoforms alpha and beta have identical cGMP-
CC       binding and catalytic domains but differ in their leucine zipper and
CC       autoinhibitory sequences and therefore differ in their dimerization
CC       substrates and kinase enzyme activity (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: Heterotetramerization is mediated by the interaction between a
CC       coiled-coil of PRKG1 and the leucine/isoleucine zipper of PPP1R12A/MBS,
CC       the myosin-binding subunit of the myosin phosphatase. {ECO:0000250}.
CC   -!- PTM: Autophosphorylation increases kinase activity. {ECO:0000250}.
CC   -!- PTM: 65 kDa monomer is produced by proteolytic cleavage. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. cGMP subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF076969; AAC31192.1; -; mRNA.
DR   RefSeq; NP_001075511.1; NM_001082042.2. [O77676-1]
DR   BMRB; O77676; -.
DR   SMR; O77676; -.
DR   STRING; 9986.ENSOCUP00000009871; -.
DR   GeneID; 100008694; -.
DR   KEGG; ocu:100008694; -.
DR   CTD; 5592; -.
DR   eggNOG; KOG0614; Eukaryota.
DR   InParanoid; O77676; -.
DR   OMA; ESCLADC; -.
DR   OrthoDB; 401933at2759; -.
DR   BRENDA; 2.7.11.12; 1749.
DR   Proteomes; UP000001811; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005246; F:calcium channel regulator activity; ISS:UniProtKB.
DR   GO; GO:0030553; F:cGMP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004692; F:cGMP-dependent protein kinase activity; ISS:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0106311; F:protein threonine kinase activity; IEA:RHEA.
DR   GO; GO:0090331; P:negative regulation of platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB.
DR   CDD; cd00038; CAP_ED; 2.
DR   CDD; cd05572; STKc_cGK; 1.
DR   Gene3D; 2.60.120.10; -; 2.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR002374; cGMP_dep_kinase.
DR   InterPro; IPR018490; cNMP-bd-like.
DR   InterPro; IPR018488; cNMP-bd_CS.
DR   InterPro; IPR000595; cNMP-bd_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR031831; PKcGMP_CC.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR035014; STKc_cGK.
DR   Pfam; PF00027; cNMP_binding; 2.
DR   Pfam; PF16808; PKcGMP_CC; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF000559; cGMP-dep_kinase; 1.
DR   PRINTS; PR00104; CGMPKINASE.
DR   SMART; SM00100; cNMP; 2.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF51206; SSF51206; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00889; CNMP_BINDING_2; 2.
DR   PROSITE; PS50042; CNMP_BINDING_3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Allosteric enzyme; Alternative splicing; ATP-binding; cGMP;
KW   cGMP-binding; Coiled coil; Cytoplasm; Disulfide bond; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P00516"
FT   CHAIN           2..671
FT                   /note="cGMP-dependent protein kinase 1"
FT                   /id="PRO_0000086116"
FT   DOMAIN          360..619
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          620..671
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   NP_BIND         167..170
FT                   /note="3',5'-cGMP 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q13976"
FT   NP_BIND         177..178
FT                   /note="3',5'-cGMP 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q13976"
FT   NP_BIND         291..294
FT                   /note="3',5'-cGMP 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q13976"
FT   NP_BIND         301..302
FT                   /note="3',5'-cGMP 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q13976"
FT   NP_BIND         366..374
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          2..102
FT                   /note="Required for dimerization"
FT                   /evidence="ECO:0000250"
FT   REGION          9..44
FT                   /note="Leucine-zipper"
FT   REGION          50..75
FT                   /note="Autoinhibitory domain"
FT                   /evidence="ECO:0000250"
FT   REGION          103..220
FT                   /note="cGMP-binding, high affinity"
FT                   /evidence="ECO:0000250"
FT   REGION          221..341
FT                   /note="cGMP-binding, low affinity"
FT                   /evidence="ECO:0000250"
FT   COILED          2..59
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        484
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         282
FT                   /note="3',5'-cGMP 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q13976"
FT   BINDING         336
FT                   /note="3',5'-cGMP 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q13976"
FT   BINDING         390
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P00516"
FT   MOD_RES         59
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P00516"
FT   MOD_RES         515
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P0C605"
FT   DISULFID        43
FT                   /note="Interchain"
FT                   /evidence="ECO:0000250"
FT   VARIANT         558
FT                   /note="F -> S"
SQ   SEQUENCE   671 AA;  76454 MW;  F8E50992F39C0D81 CRC64;
     MSELEEDFAK ILMLKEERIK ELEKRLSEKE EEIQELKRKL HKCQSVLPVP STHIGPRTTR
     AQGISAEPQT YRSFHDLRQA FRKFTKFERS KDLIKEAILD NDFMKNLELS QIQEIVDCMY
     PVEYGKDSCI IKEGDVGSLA YVMEDGKVEV TKEGVKLCTM GPGKVFGELA ILYNCTRTAT
     VKTLVNVKLW AIDRQCFQTI MMRTGLIKHT EYMEFLKSVP TFQSLPEEIL SKLADVLEET
     HYENEEYSIR QGARGDTFFI ISKGKVNVTR EDSPSEDPIF LRTLGKGDWF GEKALQGEDV
     RTANVIAAEA VTCLVIDRDS FKHLIGGLDD VSNKAYEDAE AKAKYEAEAA FFANLKLSDF
     NIIDTLGVGG FGRVELVQLK SEESKTFAMK ILKKRHIVDT RQQEHIRSEK QIMQGAHSDF
     IVRLYRTFKD SKYLYMLMEA CLGGELWTIL RDRGSFEDST TRFYTACVVE AFAYLHSKGI
     IYRDLKPENL ILDHRGYAKL VDFGFAKKIG FGKKTWTFCG TPEYVAPEII LNKGHDISAD
     YWSLGILMYE LLTGSPPFSG PDPMKTYNII LRGIDMIEFP KKIAKNAANL IKKLCRDNPS
     ERLGNLKNGV KDIQKHKWFE GFNWEGLRKG TLTPPIIPSV ASPTDTSNFD GFPEDNDEPP
     PDDNSGWDID F
//
